Marc-David Ruepp
Overview
Explore the profile of Marc-David Ruepp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farmand S, Du Preez A, Kim C, de Lucia C, Ruepp M, Stubbs B, et al.
Ageing Res Rev
. 2025 Mar;
107:102725.
PMID: 40064399
Structural and functional aspects of the hippocampus have been shown to be sensitive to the aging process, resulting in deficits in hippocampal-dependent cognition. Similarly, adult hippocampal neurogenesis (AHN), described as...
2.
Shum C, Hedges E, Allison J, Lee Y, Arias N, Cocks G, et al.
Stem Cell Reports
. 2024 Jan;
19(2):187-195.
PMID: 38242131
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disorder characterized by progressive muscular weakness due to the selective loss of motor neurons. Mutations in the gene Fused in Sarcoma...
3.
Giraud G, Roda M, Huchon P, Michelet M, Maadadi S, Jutzi D, et al.
Nucleic Acids Res
. 2023 Dec;
52(5):2290-2305.
PMID: 38113270
Phase separation regulates fundamental processes in gene expression and is mediated by the local concentration of proteins and nucleic acids, as well as nucleic acid secondary structures such as G-quadruplexes...
4.
Kim S, Mitchell S, Qamar S, Whitcomb D, Ruepp M, St George-Hyslop P, et al.
Acta Neuropathol Commun
. 2023 Dec;
11(1):199.
PMID: 38105257
The hypomethylation of fused in sarcoma (FUS) in frontotemporal lobar degeneration promotes the formation of irreversible condensates of FUS. However, the mechanisms by which these hypomethylated FUS condensates cause neuronal...
5.
Beltran-Lobo P, Hughes M, Troakes C, Croft C, Rupawala H, Jutzi D, et al.
Brain Behav Immun
. 2023 Sep;
114:414-429.
PMID: 37716378
The purinoceptor P2XR is a promising therapeutic target for tauopathies, including Alzheimer's disease (AD). Pharmacological inhibition or genetic knockdown of P2XR ameliorates cognitive deficits and reduces pathological tau burden in...
6.
Campagne S, Jutzi D, Malard F, Matoga M, Romane K, Feldmuller M, et al.
Nat Commun
. 2023 Sep;
14(1):5366.
PMID: 37666821
Pharmacologic depletion of RNA-binding motif 39 (RBM39) using aryl sulfonamides represents a promising anti-cancer therapy but requires high levels of the adaptor protein DCAF15. Consequently, novel approaches to deplete RBM39...
7.
Lin J, Khuperkar D, Pavlou S, Makarchuk S, Patikas N, Lee F, et al.
EMBO J
. 2023 May;
42(14):e113168.
PMID: 37248947
Enhanced expression of the cold-shock protein RNA binding motif 3 (RBM3) is highly neuroprotective both in vitro and in vivo. Whilst upstream signalling pathways leading to RBM3 expression have been...
8.
Jutzi D, Ruepp M
Methods Mol Biol
. 2022 Jul;
2537:1-19.
PMID: 35895255
Alternative pre-mRNA splicing allows for the production of multiple mRNAs from an individual gene, which not only expands the protein-coding potential of the genome but also enables complex mechanisms for...
9.
Solomon S, Sampathkumar N, Carre I, Mondal M, Chennell G, Vernon A, et al.
Cell Mol Life Sci
. 2022 Jul;
79(8):453.
PMID: 35895133
Background: A rare coding variant, P522R, in the phospholipase C gamma 2 (PLCG2) gene has been identified as protective against late-onset Alzheimer's disease (AD), but the mechanism is unknown. PLCG2...
10.
Mechtersheimer J, Reber S, Ruepp M
Bio Protoc
. 2021 Sep;
8(20):e3052.
PMID: 34532523
This protocol describes the application of the CRISPR-Trap from designing of the gene targeting strategy to validation of successfully edited clones that was validated on various human cell lines, among...